TME-SW
01698
XIAOMI-W
01810
BOSS ZHIPIN-W
02076
TENCENT
00700
JD HEALTH
06618
(FY)Aug 31, 2024 | (Q6)Feb 29, 2024 | (FY)Aug 31, 2023 | (Q6)Feb 28, 2023 | (FY)Aug 31, 2022 | (Q6)Feb 28, 2022 | (FY)Aug 31, 2021 | (Q6)Feb 28, 2021 | (FY)Aug 31, 2020 | (Q6)Jun 30, 2020 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 13.81%2.41B | 13.77%1.31B | 10.27%2.12B | 11.20%1.15B | 28.33%1.92B | 31.74%1.04B | 107.51%1.5B | 22.67%786.5M | --721.64M | 27.97%641.17M |
Operating income | 13.81%2.41B | 13.77%1.31B | 10.27%2.12B | 11.20%1.15B | 28.33%1.92B | 31.74%1.04B | 107.51%1.5B | 22.67%786.5M | 721.64M | 27.97%641.17M |
Cost of sales | -16.94%-1.54B | -12.89%-789.6M | -12.11%-1.31B | -12.89%-699.44M | -41.08%-1.17B | -44.17%-619.56M | -91.75%-830.29M | -41.65%-429.74M | ---433M | -30.55%-303.38M |
Operating expenses | -16.94%-1.54B | -12.89%-789.6M | -12.11%-1.31B | -12.89%-699.44M | -41.08%-1.17B | -44.17%-619.56M | -91.75%-830.29M | -41.65%-429.74M | -433M | -30.55%-303.38M |
Gross profit | 8.70%876.14M | 15.13%521.22M | 7.41%806M | 8.69%452.73M | 12.48%750.42M | 16.76%416.55M | 131.13%667.16M | 5.62%356.76M | 288.65M | 25.74%337.78M |
Selling expenses | -13.36%-40.61M | -28.00%-22.41M | -24.81%-35.83M | -12.02%-17.51M | -41.79%-28.71M | -88.88%-15.63M | -93.25%-20.25M | -21.74%-8.28M | ---10.48M | -22.60%-6.8M |
Administrative expenses | -18.44%-113.37M | -18.75%-53.26M | -9.15%-95.71M | 23.39%-44.85M | -3.61%-87.69M | -13.13%-58.55M | -100.05%-84.64M | -102.52%-51.75M | ---42.31M | 15.06%-25.55M |
Special items of operating profit | 1.21%318.77M | 2.51%143.43M | 37.96%314.96M | 1.67%139.92M | -11.40%228.3M | 22.60%137.62M | 301.58%257.68M | 144.43%112.25M | --64.17M | -3.76%45.92M |
Operating profit | 5.21%1.04B | 11.07%588.97M | 14.74%989.42M | 10.48%530.29M | 5.17%862.31M | 17.36%479.99M | 173.29%819.96M | 16.40%408.99M | 300.03M | 25.16%351.36M |
Financing cost | 10.94%-127.87M | 13.54%-58.96M | -25.21%-143.58M | -3.45%-68.19M | 19.31%-114.67M | -1.02%-65.92M | -86.03%-142.1M | -18.64%-65.25M | ---76.39M | -30.58%-55M |
Earning before tax | 7.95%913.06M | 14.70%530.01M | 13.13%845.84M | 11.60%462.1M | 10.30%747.64M | 20.46%414.07M | 203.10%677.86M | 15.99%343.74M | 223.64M | 24.21%296.36M |
Tax | -10.12%-156.99M | -36.91%-98.03M | -21.39%-142.55M | -22.47%-71.6M | -36.46%-117.43M | -50.97%-58.46M | -224.18%-86.06M | -26.36%-38.72M | ---26.55M | -136.94%-30.65M |
After-tax profit from continuing operations | 7.51%756.07M | 10.62%431.99M | 11.60%703.29M | 9.81%390.5M | 6.49%630.21M | 16.59%355.61M | 200.26%591.8M | 14.79%305.01M | 197.1M | 17.75%265.71M |
Earning after tax | 7.51%756.07M | 10.62%431.99M | 11.60%703.29M | 9.81%390.5M | 6.49%630.21M | 16.59%355.61M | 200.26%591.8M | 14.79%305.01M | 197.1M | 17.75%265.71M |
Minority profit | ---- | ---- | ---- | ---- | -57.41%10.21M | -1.90%10.21M | 8.05%23.97M | -61.49%10.41M | --22.19M | 9.64%27.03M |
Profit attributable to shareholders | 7.51%756.07M | 10.62%431.99M | 13.43%703.29M | 13.06%390.5M | 9.19%620M | 17.24%345.4M | 224.64%567.82M | 23.43%294.6M | 174.91M | 18.74%238.69M |
Basic earnings per share | 8.89%0.49 | 12.00%0.28 | 15.38%0.45 | 13.64%0.25 | 8.33%0.39 | 15.79%0.22 | 227.27%0.36 | 26.67%0.19 | 0.11 | 7.14%0.15 |
Diluted earnings per share | 8.89%0.49 | 12.00%0.28 | 15.38%0.45 | 13.64%0.25 | 14.71%0.39 | 29.41%0.22 | 209.09%0.34 | 13.33%0.17 | 0.11 | 7.14%0.15 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | -- | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- |
Auditor | -- | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.